Chlorhexidine
Brand names: Corsodyl (mouthwash 0.2%), Hibiscrub (skin scrub 4%), Hibitane, ChloraPrep (skin prep 2% + alcohol 70%)
Chlorhexidine is a widely used antiseptic for skin and mucous membrane disinfection, oral hygiene and as a preservative in some preparations.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a cationic biguanide that binds to and disrupts negatively charged bacterial cell membranes, giving broad-spectrum bactericidal activity against many Gram-positive and Gram-negative organisms.
Prescribing in practice
- Anaphylactic and other hypersensitivity reactions to chlorhexidine can occur, including with medical devices and antiseptic skin preparations, so be alert to this risk and avoid use in patients with known sensitivity.
- Alcohol-based skin preparations are flammable, so allow the solution to dry fully and avoid pooling before using diathermy or other ignition sources.
- Avoid contact with the eyes, brain, meninges and middle ear, and use mouthwash formulations as directed as they can cause reversible tooth and tongue staining and taste disturbance.
Monitoring
Routine laboratory monitoring is not required; observe for local irritation and for any signs of hypersensitivity.
Counselling the patient
- Use externally or as a mouthwash exactly as directed and avoid getting it in the eyes.
- Mouthwash may cause temporary staining of the teeth and altered taste, which generally resolves on stopping.
- Stop and seek advice if rash, swelling or breathing difficulty develops.
Evidence & guidelines
Chlorhexidine is a long-established antiseptic supported by extensive clinical use and infection-control evidence.
Reference: SmPC Corsodyl / Hibiscrub / ChloraPrep; epic3 Guidelines (2014); NICE CG139 (Healthcare-associated infections); MHRA Drug Safety Update Oct 2012 (chlorhexidine anaphylaxis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023